Projektbeschreibung
Lab-on-Chip-Plattform für die Mikromanipulation von Krebsstammzellen
Krebsstammzellen sind eine Untergruppe von Zellen unter den vielen verschiedenen Zelltypen in einem Tumor. Krebsstammzellen sind in der Lage, sich unbegrenzt zu vermehren, und sind resistenter gegen Chemotherapie, was zu Rückfällen nach der Behandlung führt. Ziel des EU-finanzierten Projekts SUMCASTEC ist die Entwicklung einer alternativen Behandlung, die selektiv ruhende Krebsstammzellen anspricht und sie anschließend zur Differenzierung anregt, um sie für Behandlungen zu sensibilisieren. Der Ansatz des Projekts zur Isolierung von Krebsstammzellen in Echtzeit basiert auf einer innovativen mikro-optofluidischen Lab-on-Chip-Plattform, die in multidisziplinärer Zusammenarbeit entwickelt wurde. Eine Lab-on-Chip-Plattform wird in der Lage sein, Spektralsignaturen von Zellen zu vergleichen und subzelluläre Merkmale abzubilden, um die Bedingungen der Mikroumgebung von Krebsstammzellen mit ultrahoher räumlicher und zeitlicher Auflösung zu modulieren.
Ziel
SUMCASTEC explores radically new approach for cancer stem cells (CSCs) real time isolation (i.e. within minutes vs current 40 days) and neutralization. A novel micro-optofluidic lab-on-chip (LOC) platform will be developed through a joint and iterative effort by biologists, clinicians and engineers. For the first time, a single LOC will be capable of delivering ultra-wide broadband radiation to compare cell spectral signatures, image subcellular features, and hence modulate CSCs microenvironment conditions with unprecedented space and time resolution. It will be driven to isolate CSCs from heterogeneous differentiated and stem cell populations, and force CSCs differentiation, ultimately inducing sensitivity to anticancer treatments. Extensive in vitro and in vivo testing along with biophysical modelling will validate the approach and establish the proof-of-principle within the project life-time, while laying the groundwork for further development of future electrosurgical tools that will be capable CSCs neutralization in tissue.
This will not only establish a new line of treatment for brain cancers such as Glioblastoma Multiforme and Medulloblastoma, whose initiation and recurrence were linked to CSCs, and that claim tremendous human and economic tolls, worldwide; it will also push the current boundaries of microbiological analysis by enabling microenvironment characterization/manipulation and real-time ionic channels monitoring without cytotoxic patch-clamping or electron microscopy.
By investing in efforts such as SUMCASTEC’s, Europe will stand at the forefront of global biomedical innovation and push through a similar miniaturization trend as the one that propelled mobile communications, yet with much deeper societal impact.
All the required competences are gathered within this consortium. The ambitious objectives of the project are planned over 42 months with a requested grant of 3 978 517,5 €.
Wissenschaftliches Gebiet
- medical and health sciencesclinical medicinesurgery
- engineering and technologyother engineering and technologiesmicrotechnologylab on a chip
- natural sciencesphysical sciencesopticsmicroscopyelectron microscopy
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-FETOPEN-1-2016-2017
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
87032 Limoges
Frankreich